Shares of Novo Nordisk sank more than 9% following the disappointing results of the ZEUS phase 3 trial. The study tested ziltivekimab, a drug aimed at reducing cardiovascular risks by targeting inflammation. Despite clearly lowering inflammatory markers, the drug did not reduce rates of heart attacks, strokes, or cardiovascular deaths compared to placebo.
ZEUS Trial Details and Outcomes
More than 6,300 patients with cardiovascular and kidney disease, all exhibiting chronic inflammation, participated in the trial. They received monthly doses of 15 mg of ziltivekimab or placebo in a double-blind setup. The primary outcome combined major cardiovascular events including death from cardiovascular causes, non-fatal heart attacks, and strokes.
While ziltivekimab significantly decreased interleukin-6 and C-reactive protein levels markers linked to inflammation it failed to translate these effects into fewer heart complications. The hazard ratio stood at 0.99, indicating no statistical difference between drug and placebo groups. Serious infections were more common in the treatment arm, consistent with the drug's mechanism, but overall mortality remained unchanged.
Ongoing Trials and Market Impact
Despite the ZEUS setback, Novo Nordisk continues its cardiovascular program with two additional trials. The HERMES study focuses on patients with heart failure and ongoing risk, while ARTEMIS evaluates post-heart attack patients at risk of further problems. Both trials are expected to report results in early 2027, which could reshape the outlook for ziltivekimab.
Following the trial news, Novo Nordisk’s stock price fell to $46.85. Analysts note that while ZEUS failed its primary endpoint, the drug’s anti-inflammatory activity might still offer benefits in other patient groups. The company maintains its adjusted operating profit forecast for 2026, signaling confidence in its broader pipeline despite this hiccup.
This material is for informational purposes only and does not constitute financial advice or recommendations.
